Sandoz announced that the FDA approved its biosimilar Tyruko® (natalizumab), biosimilar to Biogen’s Tysabri, for all indications covered by Tysabri®. It is the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis (MS). Tyruko® was developed by Polpharma Biologics pursuant to a global commercialisation agreement with Sandoz reached in 2019. As part of the agreement, Sandoz has exclusive rights to commercialise and distribute the product in all markets.
This news comes just a week after Sandoz announced its spin-off from Novartis is planned for 4 October 2023. On 21 July 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion Tyruko® to treat active relapsing remitting MS.Print Page Mail Article